ITIM
VIRX

Indiana Trust & Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Indiana Trust & Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$32 – 489
2024
Q4 		$32 Hold
200
– – ﹤0.01% 482
2024
Q3 		$46 Hold
200
– – ﹤0.01% 487
2024
Q2 		$109 Hold
200
– – ﹤0.01% 451
2024
Q1 		$204 Hold
200
– – ﹤0.01% 469
2023
Q4 		$114 Hold
200
– – ﹤0.01% 445
2023
Q3 		$208 Buy
+200
New +$271 ﹤0.01% 433

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $448M AUM 50.36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Indiana Trust & Investment Management's VIRX Position: Q1 2025 in Review

Indiana Trust & Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 200 shares — an estimated $32 sold.

Indiana Trust & Investment Management first reported a position in VIRX in Q3 2023 and held it in 6 quarters. The position peaked at $208 in Q3 2023. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Indiana Trust & Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Indiana Trust & Investment Management sold 200 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $32.
  • Indiana Trust & Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2023 and held it in 6 quarters.
  • Indiana Trust & Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $208 in Q3 2023.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Indiana Trust & Investment Management's 13F filing for Q1 2025, filed 21 May 2025.